Drugline is a fortnightly electronic drug bulletin for health professionals.
Scroll

Drugline

Drugline is a fortnightly electronic drug bulletin providing information on new medicines, new developments, current affairs, new indications, new PBS listings and deletions and general issues of importance to all health professionals. Click below to view the most recent volumes of Drugline.

Triple-Negative Breast Cancer Treatment

Drugline Volume 446

From 1 May 2022, sacituzumab govitecan is available on the Pharmaceutical Benefits Scheme (PBS) for unresectable locally advanced or metastatic triple-negative breast cancer. The PBS listing requires patients to have progressive disease following at…

Read more

PBS Listing Expanded for Nintedanib

Drugline Volume 445

The Pharmaceutical Benefits Scheme (PBS) listing has recently been expanded for nintedanib. Nintedanib was previously subsidised for the treatment of idiopathic pulmonary fibrosis; it is now covered for other types of progressive fibrosing interstitial…

Read more

Oral COVID-19 Treatment on PBS

Drugline Volume 444

From 1 May 2022, Paxlovid™ will be available on the Pharmaceutical Benefits Scheme (PBS). This will be the second oral agent PBS-listed for the treatment of COVID-19. Paxlovid™ is provisionally approved for the treatment…

Read more
Inhaler

Triple-therapy Inhaler on the PBS

Drugline Volume 443

The triple-therapy inhaler, Trelegy®, is now available on the Pharmaceutical Benefits Scheme (PBS) for the treatment of severe asthma. Trelegy® contains a corticosteroid (fluticasone furoate), a long-acting muscarinic antagonist (umeclidinium), and a long-acting beta2…

Read more
Woman Having Chemotherapy With Doctor Looking At Notes

Gemtuzumab ozogamicin on the PBS

Drugline Volume 442

A new treatment for acute myeloid leukaemia (AML) is now available on the Pharmaceutical Benefits Scheme (PBS). Gemtuzumab ozogamicin is listed for the treatment of previously untreated de novo CD33-positive AML, in combination with…

Read more

Cardiovascular Warnings for Donepezil

Drugline Volume 441

The Therapeutic Goods Administration (TGA) advises that new cardiovascular warnings have been added to the product information and consumer medicine information documents for donepezil. These updates are based on post-market adverse event data that…

Read more
Load More